Last reviewed · How we verify
GSK2646264 1%
At a glance
| Generic name | GSK2646264 1% |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects (PHASE1)
- Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2646264 1% CI brief — competitive landscape report
- GSK2646264 1% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI